中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
36期
332-332,333
,共2页
卡维地洛%心力衰竭%充血性%左心室左功能
卡維地洛%心力衰竭%充血性%左心室左功能
잡유지락%심력쇠갈%충혈성%좌심실좌공능
Cravedilol%Heart failure%Congestive%Left ventricular function
观察卡维地洛联合常规治疗方法在治疗慢性心力衰竭(CHF)中的疗效。选取我院49例慢性心力衰竭患者,随机分为常规方法治疗组21例,卡维地洛联合常规方法治疗组28例。其中,常规治疗方法包括正性肌力药,血管紧张素转换酶抑制剂(ACEI),利尿剂。联合治疗组为常规治疗方法加用卡维地洛。每隔2周随访一次,共随访7个月,用超声心动图分别测量评价治疗前后的心功能。联合治疗组和常规治疗组相比于治疗前,LVEDD、LVESD均较治疗前显著减小,LVEF较治疗前显著提高(P<0.01),相比于常规治疗组,联合治疗组治疗效果更好,差异有统计学意义(P<0.01)。
觀察卡維地洛聯閤常規治療方法在治療慢性心力衰竭(CHF)中的療效。選取我院49例慢性心力衰竭患者,隨機分為常規方法治療組21例,卡維地洛聯閤常規方法治療組28例。其中,常規治療方法包括正性肌力藥,血管緊張素轉換酶抑製劑(ACEI),利尿劑。聯閤治療組為常規治療方法加用卡維地洛。每隔2週隨訪一次,共隨訪7箇月,用超聲心動圖分彆測量評價治療前後的心功能。聯閤治療組和常規治療組相比于治療前,LVEDD、LVESD均較治療前顯著減小,LVEF較治療前顯著提高(P<0.01),相比于常規治療組,聯閤治療組治療效果更好,差異有統計學意義(P<0.01)。
관찰잡유지락연합상규치료방법재치료만성심력쇠갈(CHF)중적료효。선취아원49례만성심력쇠갈환자,수궤분위상규방법치료조21례,잡유지락연합상규방법치료조28례。기중,상규치료방법포괄정성기력약,혈관긴장소전환매억제제(ACEI),이뇨제。연합치료조위상규치료방법가용잡유지락。매격2주수방일차,공수방7개월,용초성심동도분별측량평개치료전후적심공능。연합치료조화상규치료조상비우치료전,LVEDD、LVESD균교치료전현저감소,LVEF교치료전현저제고(P<0.01),상비우상규치료조,연합치료조치료효과경호,차이유통계학의의(P<0.01)。
Objective To observe the therapy effect of carvedilol combined with conventional therapy in the treatment of chronic heart failure (CHF). Methods The selected 49 patients with chronic heart failure in our hospital were randomly divided into conventional therapy group, n=21 and combined therapy group, n=28. Among them, the conventional treatment methods includes positive inotropic drugs, angiotensin converting enzyme inhibitors (ACEI) and diuretics. The combined therapy group used carvedilol on the base of conventional therapy. Follow-up once every two weeks, a total follow-up for 7 month. Echocardiography was used to mesure and evaluate the heart function before and after treatment. Conclusions LVEDD and LVESD significantly decreased and LVEF significantly increased compared with those before treatment in both conventional therapy group and combined therapy group (P<0.01). The combined therapy group’s treatment effect is better than the conventional therapy group’s. The difference was statistically significant(P<0.01).